Pierre Gagnon - Sep 29, 2023 Form 3 Insider Report for NKGen Biotech, Inc. (GFOR)

Role
Chief Operating Officer
Signature
/s/ Pierre Gagnon, Attorney-in-fact
Stock symbol
GFOR
Transactions as of
Sep 29, 2023
Transactions value $
$0
Form type
3
Date filed
10/10/2023, 04:11 PM
Next filing
Feb 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GFOR Stock Option (right to buy) Sep 29, 2023 Common Stock 11.4K $0.32 Direct F1, F2
holding GFOR Stock Option (right to buy) Sep 29, 2023 Common Stock 150K $6.67 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is fully vested and exercisable.
F2 Mr. Gagnon was appointed as Chief Operating Officer of the Issuer effective immediately after the Effective Time (as defined in the Business Combination Agreement, dated April 14, 2023 (the "Business Combination Agreement"), by and among the Issuer, Austria Merger Sub, Inc., and NKGen Biotech, Inc.). In connection with the Closing (as defined in the Business Combination Agreement) and prior to being appointed an executive officer of the Issuer, Mr. Gagnon exchanged his options to acquire shares of common stock of NKGen Biotech, Inc. for options to acquire shares of the Issuer.
F3 One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of November 1, 2021, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

Remarks:

See attached Exhibit 24 - Power of Attorney